Parenteral prophylaxis
PreclinicalSmall molecule
Parenteral prophylaxis is one of 17 small molecule programs targeting Antibiotic Prophylaxis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Antibiotic Prophylaxis
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Zyvox
PfizerApproved
Ceftin
PPhiladelphia Eye Associates
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Ivadantin
PProcter and Gamble
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Flagyl
DDePuy Orthopaedics
Approved
Primsol
CConrado Roberto Hoffmann Filho
Approved
Ancef
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Parenteral prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Turin, Italy